Artificial Root-End Barriers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-02-28

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study retrospectively looks to determine the clinical success of ProRoot MTA used as an artificial apical barrier in teeth with immature apices.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT

NCT02702505

Reversible Pulpitis Dental Pulp Diseases

UNKNOWN PHASE4

Apexification Treatment With MTA(Mineral Trioxide Aggregate) and Ca(OH)2

NCT03855501

Immature Teeth

COMPLETED NA

Effects of RCT on Periapical Healing, Inflammatory Markers, and Kidney Function Indicators in CKD Patients With AP

NCT06446011

Apical Periodontitis Chronic Kidney Diseases

RECRUITING NA

Periapical Bone Healing After Apicectomy With and Without Retrograde Root Filling

NCT00228280

Stomatognathic Disease Mouth Disease Periapical Disease +1 more

UNKNOWN PHASE1/PHASE2

Evaluation of Apexogenesis With Human Treated Dentin Matrix in Young Permanent Molars

NCT05830695

Dentin Bridge

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The normal development and maturation of a root depends on a vital, healthy pulp. If the pulp becomes necrotic in a tooth with an immature apex, endodontic treatment can be performed using an artificial barrier technique. Mineral trioxide aggregate (MTA) has become the material of choice to accomplish this procedure, however, few studies have evaluated its clinical success. The purpose of this retrospective study was to determine the clinical success of ProRoot MTA used as an artificial apical barrier. Twenty patients were included in this study. After approximately one week of Ca(OH)2 treatment, each patient had MTA placed as an apical barrier in a tooth with a single canal and open apex followed by placement of a final restoration. Patients were recalled and evaluated for clinical signs and symptoms and osseous healing. Immediate post-treatment and recall radiographs were evaluated by two endodontists calibrated for use of the Periapical Index (PAI).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dental Cements Tooth Abnormalities

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group one

Subjects are drawn from a search of all patients treated with MTA between ages 5-40

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* a tooth with a single canal and presence of an open apex by radiograph
* Ca(OH)2 treatment for at least one week prior to obturation
* use of MTA to produce an artificial apical barrier
* placement of a final restoration
* radiographs codumenting pretreatment and immedicate post-treatment conditionof the tooth
* patients ages 5-40 years old

Exclusion Criteria

* patients younger than 5 and greater than 40 years old
* patients unable to be contacted for recall during the study
* patients with a medical condition whose health would be jeopardized by participation in the study

Minimum Eligible Age

5 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes